Atopic Dermatitis Drugs Market Size and Forecasts (2021 - 2031), Global and Regional Share, Trends, and Growth Opportunity Analysis

Coverage: Atopic Dermatitis Drugs Market covers analysis by Route of Administration (Topical, Injectable, Oral); Drug Class (Topical antibiotics, Topical antihistamines, Topical corticosteroids, Topical Moisturizers/Emollients, Topical calcineurin inhibitors, Immunomodulators, Off-Label Therapies, Systemic Agents, PDE4 inhibitor, Interleukin inhibitor, Interleukin inhibitor) , and Geography (North America, Europe, Asia Pacific, and South and Central America)

  • Report Code : TIPRE00004422
  • Category : Life Sciences
  • Status : Upcoming
  • No. of Pages : 150
Buy Now

MARKET INTRODUCTION


Atopic Dermatitis is chronic skin condition which is also known as atopic eczema. It is a type of infection (bacteria, fungi, yeast and viruses) of skin which result in itchy, red, swollen, and cracked skin. Clear fluid may come from the affected areas and also suffer from asthma, hay fever. The eczema is more common in infants and children then adults and very less in the midlife. The condition can be treated with topical steroids, topical calcineurin inhibitors (TCIs) and phototherapy there are also some Systemic drug (i.e. methotrexate, cyclosporine, and mycophenolate mofetil) used to treat the flares. The researchers have developed new drug which are currently in clinical trial pipeline.

MARKET DYNAMICS


Increasing incidence of atopic dermatitis, higher treatment compliance, growing prevalence of food allergies exacerbating atopic dermatitis, growing access to treatment in various developing countries and favorable reimbursement policies in some countries are driving the market growth of atopic dermatitis treatment worldwide. However, generic erosion, poor awareness among the patient population and adverse effects associated with the use of medication is hampering the growth of atopic dermatitis treatment market.

MARKET SCOPE


The "Global Atopic Dermatitis Drug Market Analysis to 2031" is a specialized and in-depth study with a special focus on the global market trend analysis. The report aims to provide an overview of atopic dermatitis drug market with detailed market segmentation by route of administration, drug class, and geography. The global atopic dermatitis drug market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading Atopic Dermatitis Drug market players and offers key trends and opportunities in the market

MARKET SEGMENTATION


The global atopic dermatitis drug market is segmented on the basis of Route of administration and Drug class. Based on route of administration, the market is segmented as topical, injectable and oral. On the basis of drug class, the global atopic dermatitis market is segmented into topical antibiotics, topical antihistamines, topical corticosteroids, topical moisturizers/emollients, topical calcineurin inhibitor, and immunomodulators, off-label therapies, systemic agent, PDE4 inhibitors, and interleukin inhibitors.
  • This FREE sample will include data analysis, ranging from market trends to estimates and forecasts.

REGIONAL FRAMEWORK


The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the global Atopic Dermatitis Drug market based on various segments. It also provides market size and forecast estimates from year 2021 to 2031 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The Atopic Dermatitis Drug market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 countries globally along with current trend and opportunities prevailing in the region.

The report analyzes factors affecting Atopic Dermatitis Drug market from both demand and supply side and further evaluates market dynamics effecting the market during the forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors effecting the atopic dermatitis drug market in these regions.

  • This FREE sample will include data analysis, ranging from market trends to estimates and forecasts.

MARKET PLAYERS


The reports cover key developments in the Atopic Dermatitis Drug market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies activities witnessed in the market were acquisitions, and partnership & collaborations. These activities have paved way for expansion of business and customer base of market players. The market players from atopic dermatitis drug market are anticipated to lucrative growth opportunities in the future with the rising demand for atopic dermatitis drug in the global market. Below mentioned is the list of few companies engaged in the atopic dermatitis drug market.

The report also includes the profiles of key atopic dermatitis drug market companies along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information of last 3 years, key development in past five years.
  • MYLAN
  • LEO PHARMA
  • BAYER HEALTHCARE
  • ENCORE DERMATOLOGY
  • NOVARTIS AG
  • BAUSCH HEALTH
  • ASTELLAS PHARMA INC
  • MEDA AB
  • ENCORE DERMATOLOGY
  • SANOFI
The Insight Partner's dedicated research and analysis team consist of experienced professionals with advanced statistical expertise and offer various customization options in the existing study.

  • This FREE sample will include data analysis, ranging from market trends to estimates and forecasts.

Atopic Dermatitis Drugs Report Scope

Report Attribute Details
Market size in 2023 US$ XX Million
Market Size by 2031 US$ XX Million
Global CAGR (2023 - 2031) XX%
Historical Data 2021-2022
Forecast period 2024-2031
Segments Covered By Route of Administration
  • Topical
  • Injectable
  • Oral
By Drug Class
  • Topical antibiotics
  • Topical antihistamines
  • Topical corticosteroids
  • Topical Moisturizers/Emollients
  • Topical calcineurin inhibitors
  • Immunomodulators
  • Off-Label Therapies
  • Systemic Agents
  • PDE4 inhibitor
  • Interleukin inhibitor
  • Interleukin inhibitor
Regions and Countries Covered North America
  • US
  • Canada
  • Mexico
Europe
  • UK
  • Germany
  • France
  • Russia
  • Italy
  • Rest of Europe
Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • Rest of Asia-Pacific
South and Central America
  • Brazil
  • Argentina
  • Rest of South and Central America
Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Rest of Middle East and Africa
Market leaders and key company profiles
  • MYLAN
  • LEO PHARMA
  • BAYER HEALTHCARE
  • ENCORE DERMATOLOGY
  • NOVARTIS AG
  • BAUSCH HEALTH
  • ASTELLAS PHARMA INC
  • MEDA AB
  • ENCORE DERMATOLOGY
    • Historical Analysis (2 Years), Base Year, Forecast (7 Years) with CAGR
    • PEST and SWOT Analysis
    • Market Size Value / Volume - Global, Regional, Country
    • Industry and Competitive Landscape
    • Excel Dataset
    Report Coverage

    Report Coverage

    Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends

    Segment Covered

    Segment Covered

    This text is related
    to segments covered.

    Regional Scope

    Regional Scope

    North America, Europe, Asia Pacific, Middle East & Africa, South & Central America

    Country Scope

    Country Scope

    This text is related
    to country scope.

    Trends and growth analysis reports related to Life Sciences : READ MORE..   

    The List of Companies

    1. MYLAN
    2. LEO PHARMA
    3. BAYER HEALTHCARE
    4. ENCORE DERMATOLOGY
    5. NOVARTIS AG
    6. BAUSCH HEALTH
    7. ASTELLAS PHARMA INC
    8. MEDA AB
    9. ENCORE DERMATOLOGY
    10. SANOFI

    Buy Now